THC outperformed CBD for chemotherapy-induced nerve pain in a large real-world study

Among 751 cancer patients with chemotherapy-induced neuropathy, higher THC doses produced significantly greater improvement in burning and cold sensations, daily functioning, and quality of life compared to higher CBD doses.

Geva, Ravit et al.·Biomedicines·2025·Moderate EvidenceObservational
RTHC-06531ObservationalModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Observational
Evidence
Moderate Evidence
Sample
N=1,493

What This Study Found

Both THC-high and CBD-high groups improved, but the THC-high group showed significantly greater improvement in burning sensation (p=0.024), cold sensation (p=0.008), activities of daily living (p=0.029), and quality of life (p=0.006). A significant interaction between THC and CBD was observed, with combined doses yielding greatest relief.

Key Numbers

751 patients with CIPN symptoms from 1,493 total. THC-high group: significantly better improvement in burning (p=0.024), cold sensation (p=0.008), ADL (p=0.029), QOL (p=0.006). Significant THC-CBD interaction for symptom improvement.

How They Did This

Patient-reported outcomes from Tikun Olam medical cannabis provider dataset. Of 1,493 patients, 751 with baseline CIPN symptoms were categorized into THC-high/CBD-low and CBD-high/THC-low groups. Symptom changes analyzed at six months using K-means clustering and logistic regression.

Why This Research Matters

Chemotherapy-induced neuropathy is a common dose-limiting side effect with few effective treatments. This large real-world dataset suggests THC may be more important than CBD for neuropathic pain relief, challenging the common assumption that CBD alone is sufficient for pain management.

The Bigger Picture

The medical cannabis community has increasingly emphasized CBD, partly because it lacks psychoactive effects. This study pushes back, suggesting THC plays a critical role in neuropathic pain that CBD cannot replace, though the combination may be optimal.

What This Study Doesn't Tell Us

Observational, non-randomized design. Self-reported outcomes without clinical verification. Selection bias possible in who chooses THC-dominant vs CBD-dominant products. No placebo group.

Questions This Raises

  • ?What THC:CBD ratio is optimal for different types of chemotherapy-induced neuropathy?
  • ?Could low-dose THC combined with CBD provide neuropathic relief while minimizing psychoactive effects?

Trust & Context

Key Stat:
THC-dominant products significantly outperformed CBD-dominant products for chemotherapy-induced neuropathy symptoms and quality of life
Evidence Grade:
Large real-world dataset with meaningful clinical outcomes, but observational design without randomization or blinding limits causal conclusions.
Study Age:
2025 publication.
Original Title:
Comparative Effects of THC and CBD on Chemotherapy-Induced Peripheral Neuropathy: Insights from a Large Real-World Self-Reported Dataset.
Published In:
Biomedicines, 13(8) (2025)
Database ID:
RTHC-06531

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Watches what happens naturally without intervening.

What do these levels mean? →

Frequently Asked Questions

What is chemotherapy-induced peripheral neuropathy?

CIPN is nerve damage caused by certain chemotherapy drugs, producing symptoms like burning, tingling, numbness, and cold sensitivity in hands and feet. It can be dose-limiting, meaning patients may need to reduce or stop effective cancer treatment.

Why did THC work better than CBD for nerve pain?

THC acts on CB1 receptors in the nervous system that directly modulate pain signaling. CBD has anti-inflammatory properties but may not engage pain pathways as directly. The combination showed the greatest benefit, suggesting complementary mechanisms.

Read More on RethinkTHC

Cite This Study

RTHC-06531·https://rethinkthc.com/research/RTHC-06531

APA

Geva, Ravit; Bar-Lev, Tali Hana; Lavi Kutchuk, Lee Ahuva; Schaffer, Tali; Mirelman, Dan; Pelles-Avraham, Sharon; Wolf, Ido; Bar-Lev Schleider, Lihi. (2025). Comparative Effects of THC and CBD on Chemotherapy-Induced Peripheral Neuropathy: Insights from a Large Real-World Self-Reported Dataset.. Biomedicines, 13(8). https://doi.org/10.3390/biomedicines13081921

MLA

Geva, Ravit, et al. "Comparative Effects of THC and CBD on Chemotherapy-Induced Peripheral Neuropathy: Insights from a Large Real-World Self-Reported Dataset.." Biomedicines, 2025. https://doi.org/10.3390/biomedicines13081921

RethinkTHC

RethinkTHC Research Database. "Comparative Effects of THC and CBD on Chemotherapy-Induced P..." RTHC-06531. Retrieved from https://rethinkthc.com/research/geva-2025-comparative-effects-of-thc

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.